NICE Gives Go-Ahead for Pierre Fabre’s Melanoma Combo Treatment

NICE issued a positive recommendation for Pierre Fabre’s Braftovi (encorafenib) in combination with Mektovi (binimetinib) for treating adult metastatic melanoma patients with the BRAF V600 mutation.

The institute found that the combination therapy was more effective in delaying melanoma progression and extending the lives of patients when compared to Genentech’s Zelboraf (vemurafenib). It also found the drug to be cost-effective.

Metastatic melanoma, also known as Stage IV melanoma, can spread to other parts of the body, with the liver, lungs, bones and brain most susceptible.